Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-036591
Filing Date
2024-08-12
Accepted
2024-08-12 07:03:17
Documents
71
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q avtx-20240630.htm   iXBRL 10-Q 1171332
2 EX-31.1 ex-3112q2024.htm EX-31.1 10538
3 EX-31.2 ex-3122q2024.htm EX-31.2 10324
4 EX-32.2 ex-3212q2024.htm EX-32.2 11100
10 GRAPHIC avtx-20240630_g1.jpg GRAPHIC 192450
  Complete submission text file 0001628280-24-036591.txt   7390007

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20240630.xsd EX-101.SCH 58708
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avtx-20240630_cal.xml EX-101.CAL 73796
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20240630_def.xml EX-101.DEF 345941
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20240630_lab.xml EX-101.LAB 615060
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20240630_pre.xml EX-101.PRE 472519
74 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20240630_htm.xml XML 869820
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37590 | Film No.: 241194703
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)